Together, these findings indicate that an alternate HIF2α heterodimer containing the circadian partner BMAL1 influences HIF2α activity, growth, and sensitivity to HIF2α antagonist drugs in ccRCC cells. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.